Quanterix Corporation QTRX R2KR3KPHARMA
Company Overview
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Why Investors Should Care
Revenue has grown at a 25.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.14.
Recent Developments
- Dec 2025 Revenue of $138.90M (+1.1% YoY); net profit $-107.15M.
- Trailing 12 Months Year-on-year growth — revenue +34.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 25.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 25.81% |
| 1 Year: | 34.40% |
Stock Price Performance
| 1 Year: | -40.29% |
| 6 Months: | -12.80% |
| 3 Months: | -22.07% |
| 1 Month: | -10.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 25.8% over 5 years.
CONS
- Trading 64.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QTRX Quanterix Corporation R2KR3KPHARMA | 2.86 | -1.09 | $135.26M | 0.00% | -36.49% | -46.48% | 25.81% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 7.52M | 8.64M | 10.59M | 10.88M | 12.34M | 13.54M | 14.94M | 15.92M | 15.73M | 13.13M | 31.39M | 26.13M | 27.21M | 25.37M | 27.69M | 29.55M | 23.50M | 26.65M | 28.46M | 31.03M | 31.56M | 32.07M | 34.38M | 35.81M | - | 30.33M | 24.45M | 40.15M | 43.78M | 36.41M | 32.91M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.49M | 13.18M | 23.03M | 23.82M | 20.85M | - |
| Gross Profit | - | - | 2.56M | - | 3.17M | 3.97M | 5.59M | 5.21M | 6.01M | 6.93M | 7.03M | 6.87M | 6.81M | 5.21M | 21.11M | 15.05M | 16.35M | 13.87M | 15.24M | 14.56M | 8.71M | 10.94M | 16.93M | 19.14M | 19.41M | 18.55M | 22.23M | 20.15M | - | 14.84M | 11.28M | 17.12M | 19.96M | 15.57M | 12.67M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.20M | 40.71M | 47.27M | 43.83M | 37.09M | - |
| Operating Income | -6.06M | -6.47M | -6.39M | -7.09M | -7.16M | -7.31M | -7.66M | -9.41M | -9.36M | -10.51M | -10.24M | -11.49M | -11.73M | -12.20M | 2.28M | -9.93M | -9.79M | -13.67M | -15.23M | -18.19M | -24.96M | -36.60M | -9.42M | -9.56M | -12.81M | -15.16M | -10.94M | -11.75M | - | -26.37M | -29.43M | -30.15M | -23.87M | -21.53M | -49.43M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.18M | -26.58M | -25.57M | -14.56M | -15.92M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -23.42M | -30.09M | -36.00M | -22.77M | -17.55M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.91M | -73.00K | -2.48M | 345.00K | -7.00K | - |
| Net Income | -6.39M | -6.63M | -6.61M | -7.38M | -7.20M | -7.34M | -7.66M | -9.33M | -9.40M | -10.56M | -9.87M | -10.96M | -11.61M | -12.30M | 2.20M | -9.82M | -10.10M | -11.90M | -15.66M | -18.15M | -24.90M | -35.06M | -7.27M | -5.55M | -6.72M | -11.16M | -7.39M | -8.35M | - | -20.50M | -30.01M | -33.52M | -23.12M | -17.54M | -48.93M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.37 | - | -0.41 | -0.43 | 0.07 | -0.31 | -0.29 | -0.33 | -0.43 | -0.49 | -0.67 | -0.95 | -0.16 | -0.16 | -0.18 | -0.29 | -0.19 | -0.22 | - | -0.53 | -0.77 | -0.73 | -0.49 | -0.37 | -1.04 |
| R&D Expense | 4.25M | 3.90M | 4.22M | 3.93M | 3.64M | 3.71M | 4.41M | 4.04M | 3.85M | 4.02M | 3.92M | 4.40M | 4.27M | 4.31M | 5.38M | 6.22M | 6.68M | 6.75M | 6.81M | 7.03M | 6.62M | 6.63M | 4.72M | 5.95M | 7.74M | 6.74M | 8.17M | 8.10M | - | 10.04M | 9.08M | 8.01M | - | 7.32M | 7.82M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.59M | 22.87M | 37.63M | 56.73M | 86.38M | 110.56M | 105.52M | 122.37M | 137.42M | 138.90M |
| Gross Profit | 7.75M | 9.99M | 17.95M | 26.84M | 48.18M | 61.73M | 45.36M | 74.22M | 83.10M | 64.96M |
| Operating Income | -21.71M | -26.00M | -31.55M | -41.60M | -31.58M | -58.59M | -104.26M | -45.99M | -52.62M | -125.54M |
| Net Income | -23.17M | -27.02M | -31.54M | -40.80M | -31.53M | -57.69M | -99.57M | -28.35M | -38.53M | -107.15M |
| Diluted EPS | - | - | - | -1.63 | -1.07 | -1.60 | -2.69 | -0.75 | -1.00 | -2.51 |
| R&D Expense | 16.99M | 16.30M | 15.80M | 16.19M | 20.17M | 27.98M | 26.81M | 26.06M | 31.08M | 35.92M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 91.78M | 67.61M | 169.95M | 271.05M | 501.53M | 434.20M | 428.57M | 406.53M | 418.77M |
| Total Equity | -88.64M | -115.11M | 65.87M | 41.06M | 128.66M | 206.12M | 442.79M | 357.93M | 349.96M | 330.04M | 295.73M |
| Cash & Equivalents | - | - | 79.68M | 44.43M | 109.16M | 181.58M | 396.46M | 338.74M | 174.42M | 56.71M | 29.84M |
| Long Term Debt | - | - | 4.35M | 7.62M | 7.59M | 7.69M | - | - | - | - | - |
| Total Liabilities | - | - | 25.91M | 26.55M | 41.29M | 64.92M | 60.58M | 75.26M | 78.61M | 76.50M | 123.04M |
| Current Liabilities | - | - | 19.71M | 18.12M | 19.83M | 39.80M | 36.98M | 30.96M | 38.98M | 42.01M | 74.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.74M | -22.11M | -28.72M | -26.19M | -23.36M | -47.91M | -48.61M | -18.85M | -35.16M | -77.24M |
| Investing Cash Flow | -826.00K | -1.13M | -5.45M | -25.38M | -626.00K | -6.34M | -11.09M | -148.45M | -82.27M | 50.23M |
| Financing Cash Flow | 45.92M | 73.25M | -78.00K | 116.20M | 96.24M | 270.80M | 2.31M | 2.69M | 456.00K | -708.00K |
| Capital Expenditure | -526.00K | -1.13M | -1.52M | -10.85M | -3.93M | -13.62M | -11.61M | -3.84M | -3.37M | -2.61M |
| Free Cash Flow | -18.27M | -23.24M | -30.24M | -37.03M | -27.30M | -61.52M | -60.23M | -22.69M | -38.53M | -79.85M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 44.1% | 43.7% | 47.7% | 47.3% | 55.8% | 55.8% | 43.0% | 60.7% | 60.5% | 46.8% |
| Operating Margin % | -123.5% | -113.7% | -83.8% | -73.3% | -36.6% | -53.0% | -98.8% | -37.6% | -38.3% | -90.4% |
| Net Margin % | -131.8% | -118.1% | -83.8% | -71.9% | -36.5% | -52.2% | -94.4% | -23.2% | -28.0% | -77.1% |
| ROE % | 20.1% | -41.0% | -76.8% | -31.7% | -15.3% | -13.0% | -27.8% | -8.1% | -11.7% | -36.2% |
| ROCE % | - | -36.1% | -63.8% | -27.7% | -13.7% | -12.6% | -25.9% | -11.8% | -14.4% | -36.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.69% | 3.64M | $11.92M |
| 2 | Blue Water Life Science Advisors, Lp | 7.35% | 3.47M | $11.40M |
| 3 | First Eagle Investment Management, LLC | 5.82% | 2.75M | $9.03M |
| 4 | Portolan Capital Management, LLC | 4.02% | 1.90M | $6.23M |
| 5 | Vanguard Capital Management LLC | 3.81% | 1.80M | $5.91M |
| 6 | Lionhunter Capital Management, LLC | 3.17% | 1.50M | $4.92M |
| 7 | AQR Capital Management, LLC | 2.84% | 1.34M | $4.41M |
| 8 | Geode Capital Management, LLC | 2.39% | 1.13M | $3.71M |
| 9 | Ameriprise Financial, Inc. | 2.09% | 987.42K | $3.24M |
| 10 | Marshall Wace LLP | 2.06% | 973.87K | $3.19M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QTRX
Quanterix Corporation Estimates – NASDAQ:QTRX - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5fZGQ3X1U1TUtLVll3b0JGWjhLZWxWRWRBODdmRlVzMEc5d0V4U0Ftc195ejVGT3RoVURrMTgxeWRxY2w3cFlnRWF4OUF4XzdKWm9kUTRFNk1WUzkzbDdNbzNMSWxwR1dvc0I5QnhHVHBBTFFVT0p3bA?oc=5" target="_blank">Quant…
QTRX Nov 2026 2.500 call (QTRX261120C00002500) stock historical prices and data - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE9vWFAtZUNUbjNEWWlqMmRiWGRuM3NVQ3JhS2Jld3VTT2RhTHIyRG5aMnRnWUM1Q1F5VFVEbEZySzZnSk5wVDludTQ3MUN6Q3BjR1dBWG9adWlrRVJ6UEozQWxLSi1pWlhkeWd5X2VJSUY?oc=5" target="_blank">QTRX Nov 2026 2.…
Quanterix: Trading Below 1x Sales Despite A Changing Story (NASDAQ:QTRX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQRmxTbXpPbGhXZXAzMUN0Y201a1dUdUZYYzc5X2VNSFZlWFhUWlkwUWR0cmQtLXVMclVOMkVHZVY4bms2d0hGem1OWmNGYXlWQjVGUS1XZ2VQYzNTd25nVGZZQ0h2dEgwR2RNdUlyeHlLWVZvSHFoQ1hyMUNFOVBvM3YxZVJEdjBXMDhmcE…
QTRX Nov 2026 5.000 put (QTRX261120P00005000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE41d2RwMC0wUUtoN0RLakFuS2RqekxNMXJuYkowZlhyME9sekRpTmFaSmdBc3I5VG45a3ZNa1FSbm5sbEZfWWgwQVhaLU1pRWJrY0ZLNm03TWdvb1FlaEJLMjJMSWxXUQ?oc=5" target="_blank">QTRX Nov 2026 5.000 put (QTRX…
TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPdV9jNDFVSW1RLW9MYmpLMmMwRWxYUm1zbVVhQmFWTDFCLTdSTFhzOWdsUUNoQWV6aFlKNW5jQlBjLTQtVjFMeEM2NU9ZZjktQURlQTczTHg1WEE4R0lEdGx1SVRrb0dhbHB0STRwcjc3emZmUXY5US1aZkpTZWRyNE9lOG1QTGJlcDZJMW…
Quanterix wins coverage for Alzheimer’s test (QTRX:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOU18xU2VBZ2swaldCNVRvbFd2QXkwZHpjbDV5MndjQlhYZFZWbmIxVnlTRFExaWdHc09qdFNMUms4Y3dfWEVVWjZjWXA1UDZJaDVLSG95eW4xNU1ldUwtVkdmQjNodVlqd3hfNldDdW1kSlRtbDBmbnQ2Z19PWloxSy1uOA?oc=5" targe…
QTRX — Frequently Asked Questions
What is the current share price of Quanterix Corporation (QTRX)?
As of 2026-10-23 16:27 PDT, Quanterix Corporation (QTRX) trades at $2.86 on NasdaqGM. Its 52-week range is $2.42 to $8.06.
What is the market capitalisation of QTRX?
Quanterix Corporation (QTRX) has a market capitalisation of $135.26M on NasdaqGM.
What is the P/E ratio of QTRX?
QTRX trades at a trailing price-to-earnings (P/E) ratio of -1.09. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.61.
What is the return on equity (ROE) of QTRX?
QTRX has a return on equity (ROE) of -46.48%. Its return on capital employed (ROCE) is -36.49%.
Is QTRX a good stock to buy?
This page provides a data-driven analysis of Quanterix Corporation (QTRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.